Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 927  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (703 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this Article
   References
   Article Figures
   Article Tables

 Article Access Statistics
    Viewed145    
    Printed1    
    Emailed0    
    PDF Downloaded7    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
LETTERS TO EDITOR
Year : 2019  |  Volume : 67  |  Issue : 5  |  Page : 1388-1389

Paroxysmal Dysarthria Ataxia–Tremor–Blepharospasm Syndrome in Bickerstaff Brainstem Encephalitis: A Variant of Paroxysmal Dysarthria Ataxia Syndrome


Department of Neurology, Aster Medcity, Kochi, Kerala, India

Date of Web Publication19-Nov-2019

Correspondence Address:
Dr. Boby Varkey Maramattom
Lead Consultant Neurologist , Dept of Neurology, Aster Medcity, Kochi - 682 023, Kerala
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.271246

Rights and Permissions



How to cite this article:
Maramattom BV. Paroxysmal Dysarthria Ataxia–Tremor–Blepharospasm Syndrome in Bickerstaff Brainstem Encephalitis: A Variant of Paroxysmal Dysarthria Ataxia Syndrome. Neurol India 2019;67:1388-9

How to cite this URL:
Maramattom BV. Paroxysmal Dysarthria Ataxia–Tremor–Blepharospasm Syndrome in Bickerstaff Brainstem Encephalitis: A Variant of Paroxysmal Dysarthria Ataxia Syndrome. Neurol India [serial online] 2019 [cited 2019 Dec 10];67:1388-9. Available from: http://www.neurologyindia.com/text.asp?2019/67/5/1388/271246




Sir,

A 49-year-old male was admitted with diplopia of a two month duration. Magnetic resonance imaging (MRI) of the brain showed midbrain T2/fluid attenuated inversion recovery (FLAIR) symmetrical hyperintensities with mild diffusion restriction and he was treated for a midbrain infarct [Figure 1]. Six weeks later he was readmitted with progressive difficulty in walking, generalized weakness, and diplopia along with numbness over the left side of the face after poor food intake. On examination he had bilateral ptosis, upgaze restriction, dysarthria, intention tremors in both arms, gait ataxia, and generalized areflexia. MRI showed symmetrical bithalamic and upper midbrain hyperintensity on T2/FLAIR images without diffusion restriction or contrast enhancement [Figure 1] and [Table 1]. He was administered high-dose thiamine for possible wernicke's encephalopathy and and discharged with partial improvement. One month later, he returned with worsening gait ataxia and hypersomnolence. At this point, Bickerstaff brainstem encephalitis (BBE) was considered. He was treated with a 5-day course of IV methylprednisolone without improvement. Serum ceruloplasmin came back low (8 mg/dl). However, a 24 hour urine copper estimation was normal. He then underwent six cycles of plasma exchange on alternate days. Following this, his symptoms improved and he was discharged. Other testing for HLA B51, very long chain fatty acids (VLCFAs), paraneoplastic antibodies, KF ring, and whole body PET-CT were negative. Six weeks later he returned with an intermittent head tremor and gait disturbance. These occurred usually on standing or sitting and abated on lying down; around 100–200 times a day and each lasting around 1–2 minutes. Episodes were characterized by a paroxysmal side to side head tremor, head tilt to the left, and dysarthria, along with blepharospasm lasting for <1 min [Video 1]. The episodes ended abruptly and the head tremor could be ameliorated by touching the left chin (Geste antagoniste) [Video 2]. During walking, episodes precipitated gait ataxia. The possibility of a paroxysmal dysarthria ataxia syndrome (PDA) was considered and he was started on 600 mg of carbamazepine a day. In a week, the number and intensity of episodes had reduced by >90%.[6]
Figure 1: Axial MRI images (diffusion, FLAIR, T2, and post-contrast T1) at the level of the midbrain (top panel at admission and bottom panels 1.5 months later) showing hyperintensities without contrast enhancement

Click here to view
Table 1: Differential diagnosis of symmetric thalamo-mesencephalic lesions on MRI

Click here to view




Anti-GQ1b antibody test and genetic testing for Wilson disease was negative. The final diagnosis was an atypical BBE. At follow-up 6 months later, he had improved by over 90% with carbamazepine.

PDA syndrome is characterized by recurrent, brief, stereotyped episodes of dysarthria, and limb ataxia and is classically associated with demyelinating diseases like multiple sclerosis (MS). The key lesion is in the midbrain in the vicinity of the red nucleus.[1] Paroxysmal features are thought to be caused by ephaptic transmission in the cerebello–thalamo–cortical pathways. PDA is classified into two types: (1) primary or essential PDA (pPDA, associated with episodic ataxia) or (2) secondary to underlying neurological illnesses (secondary PDA [sPDA]).[2] Other conditions associated with PDA include midbrain infarction, Behcets syndrome, and Bickerstaff encephalitis.[2],[3],[4]

sPDA may be distinguished from pPDA by adult onset, brevity of episodes (<1 min) and response to carbamazepine rather than acetazolamide (used in EA). Lacosamide, fingolimod, and lamotrigine have also been tried.[3],[4],[5] PDA syndrome may also remit spontaneously in MS. In conclusion, our patient had an atypical BBE syndrome with sPDA. MRI showed a symmetric midbrain lesion and his sPDA syndrome responded well to carbamazepine.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Gorard DA, Gibberd FB. Paroxysmal dysarthria and ataxia: Associated MRI abnormality. J Neurol Neurosurg Psychiatry 1989;52:1444-5.  Back to cited text no. 1
    
2.
Marcel C, Anheim M, Flamand-Rouvière C, Heran F, Masnou P, Boulay C,et al. Symptomatic paroxysmal dysarthria-ataxia in demyelinating diseases. J Neurol 2010;257:1369-72.  Back to cited text no. 2
    
3.
Rossi S, Studer V, Motta C, Centonze D. Paroxysmal dysarthria-ataxia syndrome resolving after fingolimod treatment. J Neurol Sci 2015;15:101-2.  Back to cited text no. 3
    
4.
Lilleker JB, Gall C, Dayanandan R, Chhetri SK, Emsley HC. Paroxysmal dysarthria ataxia syndrome responds to lacosamide. Mult Scler 2015;21:256.  Back to cited text no. 4
    
5.
Valentino P, Nisticò R, Pirritano D, Bilotti G, Del Giudice F, Sturniolo M, et al. Lamotrigine therapy for paroxysmal dysarthria caused by multiple sclerosis: A case report. J Neurol 2011;258:1349-50.  Back to cited text no. 5
    
6.
Koçer N, Islak C, Siva A, Saip S, Akman C, Kantarci O,et al. CNS involvement in neuro-Behçet syndrome: An MR study. AJNR Am J Neuroradiol 1999;20:1015-24.  Back to cited text no. 6
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow